Financial Performance Highlights (FY 2025-26)

  • Total Income: ₹110.30 crore (Previous year: ₹110.25 crore)
  • Total Expenditure: ₹95.84 crore (Previous year: ₹92.15 crore)
  • Profit Before Tax: ₹14.47 crore (Previous year: ₹18.10 crore)
  • Tax Expense: ₹3.64 crore (Previous year: ₹4.30 crore)
  • Net Profit: ₹10.83 crore (Previous year: ₹13.79 crore)
  • Earnings Per Share (Basic & Diluted): ₹8.22 (Previous year: ₹10.47)
  • Equity Share Capital: ₹13.17 crore (unchanged)

Dividend Declaration

  • Board recommended final dividend of ₹0.80 (8%) per equity share of face value ₹10 each
  • Dividend record date: June 12, 2026
  • Dividend payable subject to TDS deduction
  • Unclaimed dividend of ₹1,97,850 transferred to IEPF for 2017-18

AGM Resolutions

Ordinary Business

1. Adoption of audited financial statements for FY ended March 31, 2026

2. Declaration of final dividend of ₹0.80 per share

3. Reappointment of Mr. Rajesh Abhaychand Turakhia (DIN: 00006246) as director retiring by rotation

Special Business

4. Appointment of M/s. Harshal Doshi And Associates, Chartered Accountants (FRN: 145606W) as statutory auditors for 5 years

5. Regularization of Mrs. Chandan Mahendra Turakhia (DIN: 11500086) as Non-Executive Director

6. Approval of material related party transactions for FY 2026-27 aggregating ₹49.30 crore

7. Redesignation and appointment of Mr. Kishor Abhaychand Turakhia (DIN: 00006236) as Managing Director for 5 years from September 30, 2026

Related Party Transactions (Approved for FY 2026-27)

| Related Party | Nature of Transaction | Amount (₹) |

| Invochem Laboratory | Services | 20,00,000 |

| Suneeta Chemicals | Purchase/Sale of Goods & Services | 20,00,00,000 |

| Turakhia Bros | Purchase/Sale of Goods & Services | 5,19,80,000 |

| Gene Biotech Private Limited | Purchase/Sale of Goods, Services & Assets | 6,20,00,000 |

| Paramount Organics | Purchase/Sale of Goods & Services | 2,25,00,000 |

| Synodrug & Intermediates | Purchase/Sale of Goods & Services | 1,25,00,000 |

| Pan India Drug and chemicals Limited | Purchase/Sale of Goods | 8,00,00,000 |

Corporate Actions

  • Book Closure: September 24, 2026 to September 30, 2026 (both days inclusive)
  • E-voting Period: September 27, 2026 (9:00 AM) to September 29, 2026 (5:00 PM)
  • AGM Date: September 30, 2026 at 3:00 PM through VC/OAVM
  • Dividend Payment: October 5, 2026 to October 30, 2026

Management Changes

  • Mr. Mahendra A. Turakhia (Chairman & Managing Director) passed away on August 1, 2026
  • Mrs. Chandan Mahendra Turakhia appointed as Additional Director on August 14, 2026
  • Mr. Kishor A. Turakhia to be redesignated as Managing Director for 5 years

Auditor Information

  • Current Auditors: M/s. Jayesh R. Shah & Co., Chartered Accountants
  • Incoming Auditors: M/s. Harshal Doshi And Associates, Chartered Accountants (FRN: 145606W) appointed for 5 years
  • Secretarial Auditors: M/s. Vijaykumar Tiwari & Ass., Practicing Company Secretaries

Capital Structure

  • Authorized Capital: ₹16.00 crore (1,60,00,000 equity shares of ₹10 each)
  • Issued, Subscribed & Paid-up Capital: ₹13.17 crore (1,31,71,750 equity shares of ₹10 each)
  • Promoter Holding: 63.70 lakh shares (48.36%)

Manufacturing Facilities

  • Main manufacturing unit at Indore, Madhya Pradesh (6,100 sq.mts constructed area)
  • Two other units: Suneeta Chemicals and Paramount Organics in Indore
  • Formulation division: Gene Biotech Pvt Ltd in Poanta Sahib, Himachal Pradesh
  • Fermentation plant under development at Pithampur (60% completed)

Contingent Liabilities

  • Tax demands under dispute: ₹1.19 crore (Income tax and sales tax matters)
  • No provision recognized as management believes likelihood of outflow is not probable

Corporate Governance

  • Board comprises 6 directors (1 Managing Director, 2 Executive Directors, 3 Non-Executive Independent Directors)
  • 5 board meetings held during the year
  • CSR expenditure of ₹66.50 lakh during FY26 against obligation of ₹82.17 lakh

Financial Position (as at March 31, 2026)

  • Total Assets: ₹171.93 crore (Previous year: ₹163.28 crore)
  • Non-Current Assets: ₹82.39 crore (including Property, Plant & Equipment of ₹20.19 crore)
  • Current Assets: ₹89.55 crore (including Inventories of ₹45.08 crore and Trade Receivables of ₹39.25 crore)
  • Equity: ₹140.83 crore
  • Current Liabilities: ₹26.36 crore

Notes

  • The financial statements are prepared in compliance with Indian Accounting Standards (Ind AS)
  • The company has not accepted any public deposits during the year
  • All related party transactions were conducted at arm's length price
  • The company has adequate internal financial controls systems